Bengt Winblad

TL;DR: It is acknowledged that a single cure for Alzheimer's disease is unlikely to be found and that the approach to drug development for this disorder needs to be reconsidered, but several promising randomised controlled trials are ongoing and increased collaboration between pharmaceutical companies, basic researchers, and clinical researchers has the potential to bring us closer to developing an optimum pharmaceutical approach.

TL;DR: This work aims to acquire an understanding of the societal costs of dementia and how they affect families, health and social care services, and governments to improve the lives of people with dementia and their caregivers.

TL;DR: CAD106 is designed to stimulate amyloid-β (Aβ)-specific antibody responses while avoiding T-cell autoimmune responses in patients with mild Alzheimer's disease as mentioned in this paper.

TL;DR: It is proposed that AD could be tackled not only using combination therapies including Aβ and tau, but also considering insulin and cholesterol metabolism, vascular function, synaptic plasticity, epigenetics, neurovascular junction and blood–brain barrier targets that have been studied recently.

TL;DR: Results from active amyloid-based immunotherapy studies in preclinical models indicate that intervention appears to be more effective in early stages of amyloids accumulation, highlighting the importance of diagnosing AD as early as possible and undertaking clinical trials at this stage.